# Role of the protease-activated receptor 2 in multi-walled carbon nanotube-induced macrophage polarization ex vivo and airway fibrosis in murine allergic lung disease in vivo

**Authors:** Logan J. Tisch, Ryan D. Bartone, Silvio Antoniak, James C. Bonner

PMC · DOI: 10.3389/ftox.2026.1751684 · Frontiers in Toxicology · 2026-02-18

## TL;DR

This study shows that a receptor called PAR2 plays a key role in how carbon nanotubes worsen lung disease by causing harmful changes in immune cells and lung tissue.

## Contribution

The study identifies PAR2 as a critical mediator of MWCNT-induced macrophage polarization and fibrosis in allergic lung disease.

## Key findings

- MWCNTs enhance Th2-driven M2 macrophage polarization in a PAR2-dependent manner.
- PAR2-deficient macrophages show reduced fibroblast activation and collagen deposition.
- Myeloid-specific PAR2 deletion decreases airway fibrosis and mucus in co-exposed mice.

## Abstract

Our previous work demonstrated that co-exposure to multi-walled carbon nanotubes (MWCNTs) exacerbates allergic lung disease induced by house dust mite (HDM) extract, and that mice deficient in protease-activated receptor 2 (PAR2) show less airway fibrosis following co-exposure. In this study, we examined the role of PAR2 in mediating macrophage polarization in the presence of MWCNTs under Th2-like conditions and the subsequent effects on fibroblast activation in vitro and collagen deposition in vivo.

Bone marrow-derived macrophages (BMDMs), murine ex vivo alveolar macrophages (mexAMs), and mouse lung fibroblasts (MLFs) were isolated from wild-type (WT) and PAR2 knockout (KO) mice. Macrophages were pretreated with IL-4/IL-13 before exposure to MWCNTs, and polarization markers were analyzed through flow cytometry and Western blot analysis. Conditioned media from treated macrophages were applied to MLFs to assess fibroblast activation. In vivo, WT and myeloid-specific PAR2 KO mice were co-exposed to MWCNTs and HDM extract over 21 days, followed by analysis of bronchoalveolar lavage fluid (BALF) and lung tissue for markers of mucous cell metaplasia and airway fibrosis.

MWCNTs exacerbated IL-4/IL-13-induced M2 polarization, increasing Arg-1 and phosphorylated STAT6 levels in both BMDMs and mexAMs. This enhancement was attenuated in PAR2-deficient macrophages. Conditioned media from M2-polarized WT macrophages induced significantly higher expression of profibrotic genes, including Col1a1 and Col1a2, in MLFs compared to conditioned media from PAR2 KO macrophages. In vivo, myeloid-specific PAR2 deletion significantly decreased lung collagen deposition and mucus hypersecretion induced by MWCNT and HDM extract co-exposure.

MWCNT exposure exacerbates Th2-driven M2 macrophage polarization in a PAR2-dependent manner, leading to increased fibroblast activation and collagen deposition. Myeloid PAR2 is a critical driver of fibrotic remodeling in allergic lung disease, representing a potential therapeutic target for mitigating fibrosis in environmentally exacerbated asthma.

Diagram illustrating the general concept, ex vivo macrophage-fibroblast experiment, and in vivo exposure model for airway fibrosis. MWCNT and HDM allergens activate PAR2 on macrophages, leading to mucous metaplasia and fibrosis. Ex vivo, WT macrophages induce fibroblast activation via TGF-β1, while PAR2 knockout leads to MMP13 expression and resting fibroblasts. The in vivo model shows mice exposed to HDM extract plus MWCNT at specific time points, with analysis focused on airway collagen and mucus via histopathology.

## Linked entities

- **Genes:** F2RL1 (F2R like trypsin receptor 1) [NCBI Gene 2150], ARG1 (arginase 1) [NCBI Gene 383], STAT6 (signal transducer and activator of transcription 6) [NCBI Gene 6778], COL1A1 (collagen type I alpha 1 chain) [NCBI Gene 1277], COL1A2 (collagen type I alpha 2 chain) [NCBI Gene 1278], MMP13 (matrix metallopeptidase 13) [NCBI Gene 4322], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040]
- **Chemicals:** IL-4 (PubChem CID 171905173), HDM (PubChem CID 12111)
- **Diseases:** asthma (MONDO:0004979)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Mmp13 (matrix metallopeptidase 13) [NCBI Gene 17386] {aka Clg, MMP-13, Mmp1}, ITGAX (integrin subunit alpha X) [NCBI Gene 3687] {aka CD11C, SLEB6}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, Col1a1 (collagen, type I, alpha 1) [NCBI Gene 12842] {aka Col1a-1, Cola-1, Cola1, Mov-13, Mov13}, Gpbar1 (G protein-coupled bile acid receptor 1) [NCBI Gene 227289] {aka BG37, GPCR, GPR131, M-BAR, TGR5}, Tpsab1 (tryptase alpha/beta 1) [NCBI Gene 100503895] {aka MMCP-7, Mcp-7, Mcp7, Mcpt7}, Akt1 (Akt serine/threonine kinase 1) [NCBI Gene 11651] {aka Akt, LTR-akt, PKB, PKB/Akt, PKBalpha, Rac}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, TXLNA (taxilin alpha) [NCBI Gene 200081] {aka IL-14, IL14, TXLN}, Jak1 (Janus kinase 1) [NCBI Gene 16451] {aka BAP004, C130039L05Rik}, Par1 (pulmonary adenoma resistance 1) [NCBI Gene 112304] {aka Pas5a}, Tgfb1 (transforming growth factor, beta 1) [NCBI Gene 21803] {aka TGF-beta1, TGFbeta1, Tgfb, Tgfb-1}, Gpr34 (G protein-coupled receptor 34) [NCBI Gene 23890] {aka Lypsr1}, B2m (beta-2 microglobulin) [NCBI Gene 12010] {aka Ly-m11, beta2-m, beta2m}, Ccl11 (C-C motif chemokine ligand 11) [NCBI Gene 20292] {aka Scya11, eotaxin}, Par2 (pulmonary adenoma resistance 2) [NCBI Gene 109447], F2rl1 (F2R like trypsin receptor 1) [NCBI Gene 14063] {aka Gpcr11, PAR-2, Par2}, F2RL1 (F2R like trypsin receptor 1) [NCBI Gene 2150] {aka GPR11, PAR2}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Prtn3 (proteinase 3) [NCBI Gene 19152] {aka PR-3, PR3, mPR3}, Il4 (interleukin 4) [NCBI Gene 16189] {aka BSF-1, Il-4}, Cxcl1 (C-X-C motif chemokine ligand 1) [NCBI Gene 14825] {aka Fsp, Gro1, KC, Mgsa, N51, Scyb1}, Arg1 (arginase, liver) [NCBI Gene 11846] {aka AI, Arg-1, PGIF}, Serpinb1-ps1 (serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene) [NCBI Gene 282665] {aka EID, ovalbumin}, Csf1 (colony stimulating factor 1 (macrophage)) [NCBI Gene 12977] {aka BAP025, Csfm, MCSF, Mhdabap25, PG-M-CSF, op}, MRC1 (mannose receptor C-type 1) [NCBI Gene 4360] {aka CD206, CLEC13D, CLEC13DL, MMR, MRC1L1, bA541I19.1}, F2R (coagulation factor II thrombin receptor) [NCBI Gene 2149] {aka CF2R, HTR, PAR-1, PAR1, TR}, Csf2 (colony stimulating factor 2 (granulocyte-macrophage)) [NCBI Gene 12981] {aka CSF, Csfgm, GMCSF, Gm-CSf, MGI-IGM}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, ARG1 (arginase 1) [NCBI Gene 383], Actb (actin, beta) [NCBI Gene 11461] {aka Actx, E430023M04Rik, beta-actin}, Mucin [NCBI Gene 100508689], Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Col1a2 (collagen, type I, alpha 2) [NCBI Gene 12843] {aka Col1a-2, Cola-2, Cola2, oim}, Pik3r1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 18708] {aka PI3K, p50alpha, p55alpha, p85alpha}, Lyz2 (lysozyme 2) [NCBI Gene 17105] {aka Lys, Lysm, Lyzf2, Lyzs, Lzm, Lzm-s1}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, Stat6 (signal transducer and activator of transcription 6) [NCBI Gene 20852], Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, Il13 (interleukin 13) [NCBI Gene 16163] {aka Il-13}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}
- **Diseases:** allergic (MESH:D004342), pulmonary fibrosis (MESH:D011658), Cytotoxicity (MESH:D064420), BMDMs (MESH:D001855), pulmonary inflammation (MESH:D011014), COPD (MESH:D029424), mucous cell metaplasia (MESH:D008679), chronic respiratory diseases (MESH:D012140), Airway fibrosis (MESH:D005355), eosinophilic inflammation (MESH:D007249), lung injury (MESH:D055370), asthma (MESH:D001249), allergic lung disease (MESH:D008171)
- **Chemicals:** formalin (MESH:D005557), PVDF (MESH:C024865), PBS (MESH:D007854), hydroxyproline (MESH:D006909), penicillin (MESH:D010406), rosiglitazone (MESH:D000077154), L-ornithine (MESH:D009952), HDM extract (-), L-arginine (MESH:D001120), ethanol (MESH:D000431), bleomycin (MESH:D001761), SDS (MESH:D012967), PAS (MESH:D011478), T (MESH:D014316), proline (MESH:D011392), paraffin (MESH:D010232), pentobarbital (MESH:D010424), streptomycin (MESH:D013307), DPBS (MESH:C012939)
- **Species:** Dermatophagoides pteronyssinus (European house dust mite, species) [taxon 6956], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** C57BL/6J — Mus musculus (Mouse), Transformed cell line (CVCL_C0MW), NC7000 — Homo sapiens (Human), Finite cell line (CVCL_2904)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12957074/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12957074/full.md

## References

65 references — full list in the complete paper: https://tomesphere.com/paper/PMC12957074/full.md

---
Source: https://tomesphere.com/paper/PMC12957074